| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CTLA-4 Antigen | 40 | 2024 | 678 | 6.480 |
Why?
|
| Ipilimumab | 38 | 2024 | 759 | 6.190 |
Why?
|
| Immunotherapy | 51 | 2023 | 3535 | 4.470 |
Why?
|
| Antibodies, Monoclonal | 31 | 2024 | 4494 | 3.510 |
Why?
|
| Antineoplastic Agents, Immunological | 21 | 2022 | 1335 | 3.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 23 | 2023 | 1089 | 3.010 |
Why?
|
| Urinary Bladder Neoplasms | 21 | 2024 | 2437 | 2.990 |
Why?
|
| CD8-Positive T-Lymphocytes | 23 | 2024 | 1656 | 2.800 |
Why?
|
| Neoplasms | 43 | 2024 | 15854 | 2.380 |
Why?
|
| Tumor Microenvironment | 25 | 2024 | 2992 | 2.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2022 | 1053 | 2.210 |
Why?
|
| Carcinoma, Transitional Cell | 9 | 2021 | 1011 | 2.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 17 | 2021 | 1011 | 1.970 |
Why?
|
| Urothelium | 4 | 2020 | 272 | 1.910 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2019 | 715 | 1.890 |
Why?
|
| Drug Resistance, Neoplasm | 18 | 2024 | 5415 | 1.800 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2024 | 2415 | 1.790 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2024 | 3391 | 1.770 |
Why?
|
| B7-H1 Antigen | 14 | 2023 | 1070 | 1.720 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 8 | 2024 | 77 | 1.700 |
Why?
|
| Cancer Vaccines | 12 | 2021 | 750 | 1.650 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 6 | 2024 | 469 | 1.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2024 | 16600 | 1.540 |
Why?
|
| Kidney Neoplasms | 16 | 2024 | 3146 | 1.510 |
Why?
|
| Melanoma | 24 | 2023 | 5525 | 1.470 |
Why?
|
| Interferon-gamma | 7 | 2016 | 1180 | 1.420 |
Why?
|
| T-Lymphocyte Subsets | 11 | 2021 | 595 | 1.400 |
Why?
|
| Prostatic Neoplasms | 13 | 2023 | 5975 | 1.330 |
Why?
|
| Urologic Neoplasms | 4 | 2019 | 208 | 1.330 |
Why?
|
| Myeloid Cells | 5 | 2024 | 277 | 1.310 |
Why?
|
| Antigens, CD | 6 | 2011 | 1432 | 1.230 |
Why?
|
| B7 Antigens | 3 | 2019 | 84 | 1.190 |
Why?
|
| T-Lymphocytes | 18 | 2021 | 3929 | 1.170 |
Why?
|
| Melanoma, Experimental | 6 | 2021 | 385 | 1.170 |
Why?
|
| Lymphocyte Activation | 15 | 2021 | 1728 | 1.130 |
Why?
|
| Immunomodulation | 4 | 2017 | 253 | 1.090 |
Why?
|
| Humans | 167 | 2024 | 270832 | 1.090 |
Why?
|
| Molecular Targeted Therapy | 8 | 2020 | 2397 | 1.040 |
Why?
|
| Membrane Proteins | 7 | 2024 | 2957 | 0.960 |
Why?
|
| Tissue Extracts | 3 | 2021 | 50 | 0.960 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2024 | 151 | 0.920 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14651 | 0.920 |
Why?
|
| Carcinoma | 7 | 2020 | 2619 | 0.900 |
Why?
|
| Neoplasm Metastasis | 15 | 2024 | 5325 | 0.880 |
Why?
|
| Antigens, Neoplasm | 10 | 2016 | 1588 | 0.850 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 117 | 0.840 |
Why?
|
| Forkhead Transcription Factors | 5 | 2019 | 772 | 0.830 |
Why?
|
| Glioblastoma | 3 | 2023 | 1778 | 0.830 |
Why?
|
| Macrophages | 6 | 2024 | 1373 | 0.810 |
Why?
|
| Cryosurgery | 3 | 2021 | 186 | 0.780 |
Why?
|
| Male | 76 | 2024 | 128425 | 0.780 |
Why?
|
| Biomarkers | 12 | 2022 | 5105 | 0.770 |
Why?
|
| Cell Adhesion Molecules | 1 | 2024 | 581 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 10352 | 0.760 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 106 | 0.760 |
Why?
|
| Aged | 56 | 2024 | 73214 | 0.740 |
Why?
|
| Platinum | 2 | 2020 | 143 | 0.720 |
Why?
|
| Animals | 48 | 2024 | 62749 | 0.710 |
Why?
|
| Cell Lineage | 3 | 2019 | 706 | 0.710 |
Why?
|
| Middle Aged | 60 | 2024 | 90054 | 0.690 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.680 |
Why?
|
| Mice, Inbred C57BL | 16 | 2024 | 7216 | 0.680 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 63 | 0.680 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2019 | 19 | 0.680 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.660 |
Why?
|
| Pneumonia | 3 | 2020 | 798 | 0.650 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 219 | 0.640 |
Why?
|
| Monitoring, Immunologic | 2 | 2016 | 47 | 0.640 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 4 | 2017 | 22 | 0.630 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2019 | 1838 | 0.610 |
Why?
|
| Mice | 32 | 2024 | 35996 | 0.610 |
Why?
|
| Lymphocyte Count | 4 | 2020 | 485 | 0.600 |
Why?
|
| Clonal Evolution | 2 | 2017 | 251 | 0.600 |
Why?
|
| Liver Neoplasms | 6 | 2022 | 4795 | 0.600 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 2165 | 0.600 |
Why?
|
| Single-Cell Analysis | 5 | 2024 | 537 | 0.590 |
Why?
|
| Signal Transduction | 14 | 2024 | 12198 | 0.590 |
Why?
|
| Combined Modality Therapy | 15 | 2022 | 9041 | 0.580 |
Why?
|
| Female | 69 | 2024 | 148552 | 0.580 |
Why?
|
| Cell Line, Tumor | 17 | 2024 | 14854 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 5234 | 0.570 |
Why?
|
| Organoplatinum Compounds | 1 | 2019 | 703 | 0.560 |
Why?
|
| Neutrophils | 1 | 2021 | 875 | 0.560 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 263 | 0.550 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 42 | 0.550 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 30953 | 0.550 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2021 | 629 | 0.550 |
Why?
|
| Biomarkers, Tumor | 15 | 2021 | 10694 | 0.550 |
Why?
|
| Neoadjuvant Therapy | 12 | 2024 | 5206 | 0.540 |
Why?
|
| Interleukin-7 | 1 | 2016 | 93 | 0.530 |
Why?
|
| Autoantibodies | 1 | 2019 | 590 | 0.530 |
Why?
|
| Genetic Markers | 2 | 2019 | 1015 | 0.510 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 104 | 0.500 |
Why?
|
| Pilot Projects | 7 | 2024 | 2851 | 0.490 |
Why?
|
| Membrane Glycoproteins | 5 | 2024 | 1100 | 0.490 |
Why?
|
| Salvage Therapy | 3 | 2019 | 2118 | 0.480 |
Why?
|
| Flow Cytometry | 10 | 2019 | 3076 | 0.480 |
Why?
|
| DNA-Binding Proteins | 3 | 2024 | 5037 | 0.460 |
Why?
|
| Yttrium Radioisotopes | 1 | 2015 | 210 | 0.460 |
Why?
|
| Preoperative Care | 2 | 2019 | 1550 | 0.450 |
Why?
|
| Lung Neoplasms | 15 | 2023 | 11774 | 0.440 |
Why?
|
| Treatment Outcome | 28 | 2024 | 33837 | 0.440 |
Why?
|
| Th1 Cells | 3 | 2021 | 260 | 0.430 |
Why?
|
| Transcription Factors | 3 | 2024 | 5489 | 0.430 |
Why?
|
| Adult | 39 | 2024 | 81579 | 0.420 |
Why?
|
| Skin Neoplasms | 5 | 2023 | 4838 | 0.420 |
Why?
|
| Vaccines, DNA | 2 | 2013 | 111 | 0.420 |
Why?
|
| Adenocarcinoma | 7 | 2024 | 7934 | 0.420 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 169 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 5531 | 0.390 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 1138 | 0.380 |
Why?
|
| Antibodies | 4 | 2014 | 819 | 0.380 |
Why?
|
| Orchiectomy | 1 | 2011 | 226 | 0.380 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 662 | 0.370 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 7812 | 0.370 |
Why?
|
| Neoplasm Staging | 13 | 2022 | 13979 | 0.360 |
Why?
|
| Myocarditis | 2 | 2024 | 194 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2021 | 7244 | 0.360 |
Why?
|
| Neoplasms, Experimental | 3 | 2018 | 790 | 0.350 |
Why?
|
| Immune Tolerance | 3 | 2015 | 431 | 0.340 |
Why?
|
| Survival Rate | 12 | 2022 | 12516 | 0.340 |
Why?
|
| BCG Vaccine | 3 | 2017 | 426 | 0.340 |
Why?
|
| Proteins | 2 | 2011 | 2047 | 0.340 |
Why?
|
| Interferon Type I | 2 | 2024 | 283 | 0.340 |
Why?
|
| Cytokines | 7 | 2019 | 2835 | 0.330 |
Why?
|
| Immunologic Memory | 4 | 2020 | 380 | 0.330 |
Why?
|
| Colitis | 3 | 2022 | 344 | 0.320 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2021 | 1134 | 0.320 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 272 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2020 | 3148 | 0.310 |
Why?
|
| Receptors, OX40 | 2 | 2019 | 51 | 0.300 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 1718 | 0.300 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 7466 | 0.290 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2021 | 967 | 0.290 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 253 | 0.290 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 426 | 0.280 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 4370 | 0.280 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 1487 | 0.280 |
Why?
|
| CD8 Antigens | 1 | 2007 | 173 | 0.270 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 104 | 0.270 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 4981 | 0.270 |
Why?
|
| Esophagogastric Junction | 2 | 2021 | 555 | 0.270 |
Why?
|
| Immunophenotyping | 5 | 2019 | 1729 | 0.270 |
Why?
|
| Clone Cells | 4 | 2020 | 589 | 0.260 |
Why?
|
| Mutation | 11 | 2024 | 15850 | 0.260 |
Why?
|
| Survival Analysis | 11 | 2020 | 9304 | 0.260 |
Why?
|
| Muscles | 1 | 2007 | 461 | 0.260 |
Why?
|
| Piperidines | 2 | 2024 | 1090 | 0.260 |
Why?
|
| Interleukin-10 | 1 | 2008 | 481 | 0.260 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 315 | 0.240 |
Why?
|
| Disease-Free Survival | 10 | 2023 | 10249 | 0.240 |
Why?
|
| Patient Safety | 2 | 2021 | 655 | 0.240 |
Why?
|
| Indoles | 3 | 2018 | 1034 | 0.230 |
Why?
|
| Abiraterone Acetate | 1 | 2024 | 88 | 0.230 |
Why?
|
| Azetidines | 1 | 2024 | 88 | 0.220 |
Why?
|
| Myositis | 1 | 2024 | 84 | 0.220 |
Why?
|
| Receptors, IgG | 2 | 2024 | 116 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 9069 | 0.220 |
Why?
|
| Prostate | 1 | 2009 | 1138 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2021 | 9434 | 0.220 |
Why?
|
| Neuroimmunomodulation | 1 | 2023 | 72 | 0.210 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 228 | 0.210 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 114 | 0.210 |
Why?
|
| Testicular Neoplasms | 1 | 2006 | 554 | 0.200 |
Why?
|
| Histone Demethylases | 1 | 2023 | 145 | 0.200 |
Why?
|
| Phenotype | 5 | 2024 | 6452 | 0.200 |
Why?
|
| Prognosis | 14 | 2023 | 22462 | 0.200 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 294 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 2364 | 0.200 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 148 | 0.200 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2021 | 161 | 0.190 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3852 | 0.190 |
Why?
|
| Prednisone | 1 | 2024 | 1037 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2007 | 753 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 126 | 0.190 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.190 |
Why?
|
| Peptides | 2 | 2018 | 1525 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 331 | 0.190 |
Why?
|
| Monocytes | 2 | 2022 | 787 | 0.180 |
Why?
|
| Mice, Knockout | 4 | 2020 | 5836 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2024 | 4069 | 0.180 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 20 | 0.180 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 115 | 0.180 |
Why?
|
| Cell Dedifferentiation | 1 | 2020 | 101 | 0.180 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 36 | 0.170 |
Why?
|
| SMARCB1 Protein | 1 | 2020 | 109 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Diarrhea | 2 | 2020 | 730 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 458 | 0.170 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 69 | 0.170 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 227 | 0.160 |
Why?
|
| Thymus Gland | 2 | 2019 | 310 | 0.160 |
Why?
|
| Antigens | 1 | 2019 | 283 | 0.160 |
Why?
|
| Genomics | 3 | 2020 | 2817 | 0.160 |
Why?
|
| Standard of Care | 2 | 2018 | 274 | 0.160 |
Why?
|
| Osteoclasts | 1 | 2019 | 158 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 240 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 4 | 2016 | 2467 | 0.160 |
Why?
|
| Bone Neoplasms | 3 | 2021 | 2667 | 0.160 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 73 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 1019 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2020 | 7291 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 15241 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2021 | 331 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2023 | 6251 | 0.150 |
Why?
|
| Carcinoma, Medullary | 1 | 2020 | 245 | 0.150 |
Why?
|
| Human Body | 1 | 2017 | 2 | 0.150 |
Why?
|
| Immune System | 3 | 2018 | 276 | 0.150 |
Why?
|
| Forecasting | 1 | 2021 | 705 | 0.150 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2018 | 94 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 532 | 0.150 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 15 | 0.150 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.150 |
Why?
|
| Atlases as Topic | 1 | 2017 | 46 | 0.150 |
Why?
|
| Up-Regulation | 4 | 2017 | 2455 | 0.150 |
Why?
|
| Eukaryotic Cells | 1 | 2017 | 51 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2022 | 447 | 0.150 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 5156 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 686 | 0.150 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 19 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2023 | 1425 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2021 | 314 | 0.150 |
Why?
|
| Everolimus | 2 | 2017 | 438 | 0.150 |
Why?
|
| Newcastle disease virus | 1 | 2017 | 7 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 676 | 0.150 |
Why?
|
| Panniculitis | 1 | 2017 | 58 | 0.140 |
Why?
|
| Idarubicin | 1 | 2019 | 459 | 0.140 |
Why?
|
| Nitriles | 1 | 2022 | 943 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2023 | 4125 | 0.140 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.140 |
Why?
|
| Pyrroles | 2 | 2018 | 592 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 192 | 0.140 |
Why?
|
| Gene Expression | 3 | 2019 | 3678 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 172 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 2671 | 0.140 |
Why?
|
| Benzamides | 1 | 2022 | 1882 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1084 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 1996 | 115 | 0.130 |
Why?
|
| DNA Replication | 1 | 2020 | 771 | 0.130 |
Why?
|
| Esophageal Neoplasms | 2 | 2021 | 3237 | 0.130 |
Why?
|
| Neoplasm Transplantation | 3 | 2015 | 1565 | 0.130 |
Why?
|
| Young Adult | 9 | 2021 | 22052 | 0.130 |
Why?
|
| Herpes Simplex | 1 | 1996 | 101 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 317 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2017 | 271 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 1821 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 361 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 165 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 759 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 64 | 0.120 |
Why?
|
| Immunologic Factors | 4 | 2022 | 668 | 0.120 |
Why?
|
| Imidazoles | 2 | 2018 | 1055 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 322 | 0.120 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 128 | 0.120 |
Why?
|
| Disease Progression | 4 | 2021 | 6895 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1142 | 0.120 |
Why?
|
| Autoantigens | 1 | 1996 | 245 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1379 | 0.120 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 235 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1739 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2020 | 2034 | 0.120 |
Why?
|
| Graft vs Host Disease | 3 | 2020 | 2804 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1133 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1380 | 0.120 |
Why?
|
| Intestine, Small | 1 | 1997 | 526 | 0.110 |
Why?
|
| Sarcoma | 2 | 2021 | 1839 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2015 | 958 | 0.110 |
Why?
|
| Inflammation | 2 | 2021 | 2525 | 0.110 |
Why?
|
| Risk Factors | 5 | 2020 | 17819 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2021 | 3067 | 0.110 |
Why?
|
| Cisplatin | 1 | 2020 | 2496 | 0.110 |
Why?
|
| Cytarabine | 1 | 2019 | 2014 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 176 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2016 | 324 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1468 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 2022 | 0.110 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 417 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 1004 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2017 | 1690 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2022 | 1264 | 0.100 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 154 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1735 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 3231 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2020 | 6983 | 0.100 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2011 | 25 | 0.100 |
Why?
|
| Prostatectomy | 1 | 2017 | 1006 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 3537 | 0.100 |
Why?
|
| Nephrectomy | 2 | 2023 | 808 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1346 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2017 | 247 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 408 | 0.100 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2012 | 163 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 831 | 0.090 |
Why?
|
| ras Proteins | 1 | 2015 | 801 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 746 | 0.090 |
Why?
|
| Radiosurgery | 2 | 2019 | 1368 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1965 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 2473 | 0.090 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2010 | 15 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2010 | 73 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2010 | 99 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 398 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2012 | 421 | 0.090 |
Why?
|
| Cystectomy | 2 | 2020 | 632 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2012 | 549 | 0.080 |
Why?
|
| Lymphoma | 1 | 2017 | 1513 | 0.080 |
Why?
|
| Injections, Intradermal | 1 | 2008 | 51 | 0.080 |
Why?
|
| Erythema | 1 | 2008 | 48 | 0.080 |
Why?
|
| Azacitidine | 3 | 2021 | 1218 | 0.080 |
Why?
|
| Rifampin | 1 | 2009 | 220 | 0.080 |
Why?
|
| Epitope Mapping | 1 | 2008 | 110 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 2316 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3904 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 7786 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 616 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2008 | 171 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 3070 | 0.080 |
Why?
|
| Minocycline | 1 | 2009 | 189 | 0.080 |
Why?
|
| DNA Copy Number Variations | 3 | 2020 | 1546 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 1527 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 164 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2014 | 1669 | 0.070 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 85 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2008 | 385 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 2215 | 0.070 |
Why?
|
| Immunologic Surveillance | 1 | 2007 | 61 | 0.070 |
Why?
|
| Anilides | 2 | 2022 | 296 | 0.070 |
Why?
|
| Quality of Life | 5 | 2022 | 4740 | 0.070 |
Why?
|
| Genes, MHC Class I | 1 | 2007 | 48 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2015 | 1199 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1858 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2089 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 383 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 39703 | 0.070 |
Why?
|
| Lung | 3 | 2020 | 3270 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 6478 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 6767 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 16188 | 0.070 |
Why?
|
| Epitopes | 1 | 2008 | 707 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2018 | 753 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4386 | 0.070 |
Why?
|
| Perfusion | 1 | 2007 | 285 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7927 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2020 | 4356 | 0.060 |
Why?
|
| Angiography | 1 | 2007 | 351 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 5802 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3924 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 451 | 0.060 |
Why?
|
| Intestinal Mucosa | 2 | 2023 | 1124 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2022 | 1066 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 692 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2020 | 6031 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 5186 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2024 | 27 | 0.060 |
Why?
|
| Antigen Presentation | 2 | 2014 | 289 | 0.060 |
Why?
|
| Ligands | 2 | 2018 | 1057 | 0.060 |
Why?
|
| Bacteremia | 1 | 2009 | 722 | 0.060 |
Why?
|
| International Cooperation | 2 | 2017 | 324 | 0.060 |
Why?
|
| Italy | 1 | 2023 | 186 | 0.060 |
Why?
|
| Risk | 2 | 2018 | 1913 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1372 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2016 | 1070 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 318 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2003 | 311 | 0.050 |
Why?
|
| Vaccination | 1 | 2009 | 1154 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 1439 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 4631 | 0.050 |
Why?
|
| Pyridines | 2 | 2022 | 1311 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2021 | 2431 | 0.050 |
Why?
|
| Testis | 1 | 2006 | 753 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Transcriptome | 2 | 2021 | 1933 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 95 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 431 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3972 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 879 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5566 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2021 | 228 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 3661 | 0.050 |
Why?
|
| Taxoids | 1 | 2024 | 1008 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 718 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2347 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 95 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 298 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2020 | 257 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 4967 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 46 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 161 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5099 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 355 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2020 | 13365 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 3543 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 84 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 508 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 5838 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2018 | 35 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 865 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2018 | 163 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2020 | 600 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 621 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 230 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 553 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3646 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2018 | 2744 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 203 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 726 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1997 | 76 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 210 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 174 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1313 | 0.040 |
Why?
|
| Chimera | 1 | 2017 | 152 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1054 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 3171 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 191 | 0.030 |
Why?
|
| Hominidae | 1 | 1996 | 43 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1443 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 340 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1996 | 97 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1996 | 83 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 431 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1996 | 184 | 0.030 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 103 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 251 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 1996 | 79 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1996 | 291 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 447 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1213 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 582 | 0.030 |
Why?
|
| Th2 Cells | 1 | 1996 | 253 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 322 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3343 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 13107 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 844 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6831 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 319 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1111 | 0.030 |
Why?
|
| Melphalan | 1 | 2018 | 875 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 804 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 268 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 1194 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 981 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 1996 | 435 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2017 | 661 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 690 | 0.030 |
Why?
|
| United States | 1 | 2012 | 15994 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 566 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 826 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2015 | 298 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 1323 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 683 | 0.030 |
Why?
|
| Plasmids | 1 | 1996 | 952 | 0.030 |
Why?
|
| Quinolines | 1 | 2017 | 402 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 100 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1364 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 134 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 683 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 1588 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 157 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Fatigue | 1 | 2019 | 1280 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 745 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5775 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2049 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 405 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2018 | 1108 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2015 | 957 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2377 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 3033 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 1348 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 2337 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 721 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2014 | 738 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 4882 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 1997 | 1888 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 533 | 0.020 |
Why?
|
| Base Sequence | 1 | 1996 | 5484 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 3415 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1160 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1820 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 531 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 5087 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1377 | 0.020 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2007 | 33 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5486 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2428 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 1885 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6412 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 365 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 3122 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2084 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2646 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 890 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4186 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1997 | 4190 | 0.020 |
Why?
|
| Apoptosis | 1 | 2020 | 7828 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5437 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 1435 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 32534 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4251 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1996 | 42 | 0.010 |
Why?
|
| Gorilla gorilla | 1 | 1996 | 15 | 0.010 |
Why?
|
| Antigens, CD1 | 1 | 1996 | 48 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1996 | 189 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1996 | 664 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 1996 | 213 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1585 | 0.010 |
Why?
|